Nifib (Nintedanib)

Nintedanib, the active ingredient in Nifib, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease and certain non‑small cell lung cancers.

GNH USA supplies Nifib as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nifib acts on pathways that drive fibrosis and tumor growth, providing therapeutic benefit in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.

Nifib may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may accompany meals. - Vomiting: occasional episodes. - Decreased appetite: reduced desire to eat. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Bleeding events: gastrointestinal or other hemorrhage. - Cardiovascular events: hypertension or arterial thrombotic events.

Before initiating Nifib therapy, clinicians should consider several safety measures. - Monitor liver function: perform baseline and periodic ALT/AST tests. - Assess bleeding risk: evaluate history of ulcers or anticoagulant use. - Check blood pressure: monitor for hypertension during therapy. - Evaluate renal function: adjust if severe impairment. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nifib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs and antiplatelet agents: increase potential for gastrointestinal bleeding. - St. John’s wort: may lower drug concentrations.